Ibrutinib and Lenalidomide in Treating Patients With Myelodysplastic Syndrome
Status:
Completed
Trial end date:
2019-11-17
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of ibrutinib when giving together
with lenalidomide in treating patients with myelodysplastic syndrome. Ibrutinib may stop the
growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in
chemotherapy, such as lenalidomide, work in different ways to stop the growth of cancer
cells, either by killing the cells, by stopping them from dividing, or by stopping them from
spreading. Giving ibrutinib and lenalidomide may work better in treating patients with
myelodysplastic syndrome.
Phase:
Phase 1
Details
Lead Sponsor:
Brian Jonas University of California, Davis
Collaborators:
Celgene National Cancer Institute (NCI) Pharmacyclics LLC.